Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8431 to 8445 of 8853 results

  1. Venous thromboembolism (recurrent) - idraparinux sodium [ID395]

    Discontinued Reference number: GID-TAG384

    Technology appraisal guidance
    Discontinued

  2. Human Growth Hormone for Idiopathic Short Stature (in children)[ID317]

    Discontinued Reference number: GID-TA11256

    Technology appraisal guidance
    Discontinued

  3. Osteoarthritis - diacerein [ID332]

    Discontinued Reference number: GID-TAG250

    Technology appraisal guidance
    Discontinued

  4. Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

    Discontinued Reference number: GID-TAG417

    Technology appraisal guidance
    Discontinued

  5. Atrial fibrillation - idraparinux sodium [ID375]

    Discontinued Reference number: GID-TAG383

    Technology appraisal guidance
    Discontinued

  6. Temozolomide for the treatment of advanced and metastatic melanoma [ID316]

    Discontinued Reference number: GID-TAG401

    Technology appraisal guidance
    Discontinued

  7. Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]

    Discontinued Reference number: GID-TA11240

    Technology appraisal guidance
    Discontinued

  8. Capecitabine for the treatment of advanced pancreatic cancer [ID127]

    Discontinued Reference number: GID-TA11239

    Technology appraisal guidance
    Discontinued

  9. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID977]

    Discontinued Reference number: GID-TA11238

    Technology appraisal guidance
    Discontinued

  10. Mastocytosis (systemic) - masitinib [ID781]

    Discontinued Reference number: GID-TA10019

    Technology appraisal guidance
    Discontinued

  11. Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]

    Discontinued Reference number: GID-TA10767

    Technology appraisal guidance
    Discontinued

  12. Stye: antimicrobial prescribing

    Discontinued Reference number: GID-NG10167

    Antimicrobial prescribing guideline
    Discontinued

  13. Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]

    Discontinued Reference number: GID-TA11339

    Technology appraisal guidance
    Discontinued

  14. Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

    Discontinued Reference number: GID-HST10033

    Highly specialised technologies guidance
    Discontinued

  15. Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]

    Discontinued Reference number: GID-TA10851

    Technology appraisal guidance
    Discontinued